Steiner M, Matthes-Martin S, Attarbaschi A, Minkov M, Grois N, Unger E, Holter W, Vormoor J, Wawer A, Ouachee M, Woessmann W, Gadner H
1St Anna Children's Hospital, Vienna, Austria.
Bone Marrow Transplant. 2005 Aug;36(3):215-25. doi: 10.1038/sj.bmt.1705015.
Children with multisystem Langerhans cell histiocytosis (LCH) and risk organ involvement who fail to respond to conventional chemotherapy have an extremely poor prognosis. Myeloablative stem cell transplantation (SCT) as a possible salvage approach for these patients has been associated with a high risk of transplant-related mortality. Therefore, allogeneic stem cell transplantation following a reduced-intensity conditioning regimen (RIC-SCT) has recently been performed as an alternative salvage approach. We report on the experience with allogeneic RIC-SCT in nine pediatric high-risk LCH patients. Conditioning regimen included fludarabine in all patients, melphalan in eight patients, total lymphoid irradiation in six patients, total body irradiation in two, antithymocyte globulin in five, and Campath in four patients. RIC-SCT was well tolerated with regard to common procedure-related complications. Two patients died 50 and 69 days after RIC-SCT, respectively. Seven out of the nine patients survived and showed no signs of disease activity (including one with nonengraftment and full autologous hematopoietic recovery) after median follow-up of 390 days post-SCT. Based on this observation, we conclude that RIC-SCT is a feasible procedure with low transplant-related morbidity and mortality and a promising new salvage approach for high-risk LCH patients with resistant risk organ involvement.
患有多系统朗格汉斯细胞组织细胞增多症(LCH)且有风险器官受累且对传统化疗无反应的儿童预后极差。清髓性干细胞移植(SCT)作为这些患者可能的挽救方法,与移植相关死亡率的高风险相关。因此,最近已采用减低强度预处理方案后的异基因干细胞移植(RIC-SCT)作为一种替代挽救方法。我们报告了9例儿科高危LCH患者接受异基因RIC-SCT的经验。预处理方案包括所有患者均使用氟达拉滨,8例患者使用美法仑,6例患者使用全淋巴照射,2例患者使用全身照射,5例患者使用抗胸腺细胞球蛋白,4例患者使用Campath。RIC-SCT对常见的与操作相关的并发症耐受性良好。两名患者分别在RIC-SCT后50天和69天死亡。9例患者中有7例存活,在SCT后中位随访390天,均无疾病活动迹象(包括1例未植入且完全自体造血恢复的患者)。基于这一观察结果,我们得出结论,RIC-SCT是一种可行的方法,具有低移植相关发病率和死亡率,是治疗有耐药风险器官受累的高危LCH患者的一种有前景的新挽救方法。